- Home
- PDFS vs GHRS Comparison
PDFS vs GHRS Comparison
Compare PDFS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDFS | GHRS |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PDFS | GHRS |
|---|---|---|
| Price | $51.45 | $28.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $39.67 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 507.6K | 268.5K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.13 | N/A |
| Revenue Next Year | $18.92 | N/A |
| P/E Ratio | $400.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.19 | $11.32 |
| 52 Week High | $71.69 | $31.00 |
Technical Indicators
Market Signals| Indicator | PDFS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 59.91 |
| Support Level | N/A | $25.66 |
| Resistance Level | N/A | $28.96 |
| Average True Range (ATR) | 0.00 | 1.44 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 0.00 | 46.78 |
Price Performance
Historical ComparisonAbout PDFS PDF Solutions Inc.
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.